The GoodRx Pharmacist - March 10, 2017
According to The American Diabetes Association, as of 2012, type 2 diabetes affected 29.1 million Americans, 9.3% of the population. Every year another 1.4 million Americans are diagnosed with type 2 diabetes, which can lead to live-threatening complications like high-blood pressure, kidney disease, high cholesterol, or loss of vision.
Recently, the FDA approved Qtern (dapagliflozin and saxagliptin), a new combination prescription medication for adults with type 2 diabetes. See More
The GoodRx Pharmacist - July 06, 2016
According to the FDA, canagliflozin and dapagliflozin may cause an increased risk of acute kidney injury. The previous warning for canagliflozin was for an increased risk of foot and leg amputations—all serious stuff. See More
The GoodRx Pharmacist - May 21, 2015
On May 15, 2015, the FDA issued a warning for the newest class of diabetes medications, SGLT2 inhibitors.
According to the FDA, the medications in this class may lead to a serious and life-threatening condition known as ketoacidosis.
Which medications are considered SGLT2 inhibitors?
These medications also contain SGLT2 inhibitors in combination with other active ingredients:
- Glyxambi (empagliflozin/linagliptin)
- Invokamet (canagliflozin/metformin)
- Xigduo XR (dapagliflozin/metformin)
What should I do if I am taking one of these medications?
If you are taking one of the medications listed above DO NOT stop your medication without talking to your doctor. See More
Elizabeth Davis - August 20, 2014
For many Americans with health insurance, more than 40 popular brand-name drugs may no longer be covered starting in January 2015. Express Scripts and Caremark, companies that handle pharmacy benefits for more than 200 million Americans, are removing over 40 drugs from their formularies at the end of 2014. This is in addition to the more than 50 drugs removed last year.
What are Express Scripts and Caremark?
Express Scripts and Caremark are companies that administer prescription drug benefits for many health insurance companies and Tricare. See More
The GoodRx Pharmacist - August 08, 2014
Jardiance (empagliflozin) was approved by the FDA on August 1, 2014 for the treatment of type 2 diabetes.
How does Jardiance work?
It works with the body’s natural process of urination to help remove more excess sugar from the body rather than allowing it to be reabsorbed by your kidneys. See More
Dr. Sharon Orrange - March 14, 2014
With 25 million Americans with adult-onset diabetes I guess it’s great we have so many new medications coming down the pipeline. As a primary care doctor, even my head is spinning learning the details of the newest diabetes medications but it’s exciting . . . and here is another one.
The GoodRx Pharmacist - January 10, 2014
Farxiga (dapagliflozin) was approved by the FDA for the treatment of type II diabetes this week, after a previous denial in January 2012 due to bladder cancer concerns. Here’s what you need to know:
How does Farxiga work, and are there any similar drugs available?
Dapagliflozin is part of a newer class of drugs: Sodium Glucose Co-Transporter 2 inhibitors (SGLT2 inhibitors). Invokana (canagliflozin), approved in March 2013, is the only other medication in this class. See More